"Dabigatran" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A THROMBIN inhibitor which acts by binding and blocking thrombogenic activity and the prevention of thrombus formation. It is used to reduce the risk of stroke and systemic EMBOLISM in patients with nonvalvular atrial fibrillation.
| Descriptor ID |
D000069604
|
| MeSH Number(s) |
D03.383.725.192 D03.633.100.103.280
|
| Concept/Terms |
Dabigatran- Dabigatran
- N-((2-(((4-(aminoiminomethyl)phenyl)amino)methyl)-1-methyl-1H-benzimidazol-5-yl)carbonyl)-N-2-pyridinyl-beta-alanine
|
Below are MeSH descriptors whose meaning is more general than "Dabigatran".
Below are MeSH descriptors whose meaning is more specific than "Dabigatran".
This graph shows the total number of publications written about "Dabigatran" by people in this website by year, and whether "Dabigatran" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 2 | 2 |
| 2015 | 1 | 1 | 2 |
| 2016 | 0 | 2 | 2 |
| 2017 | 2 | 0 | 2 |
| 2018 | 0 | 2 | 2 |
| 2019 | 1 | 2 | 3 |
| 2020 | 2 | 0 | 2 |
| 2021 | 1 | 1 | 2 |
| 2022 | 2 | 0 | 2 |
| 2024 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Dabigatran" by people in Profiles.
-
Predictors of adherence to direct oral anticoagulants after cardiovascular or bleeding events in Medicare Advantage Plan enrollees with atrial fibrillation. J Manag Care Spec Pharm. 2024 May; 30(5):408-419.
-
Dabigatran for Treatment and Secondary Prevention of Venous Thromboembolism in Pediatric Congenital Heart Disease. J Am Heart Assoc. 2024 Feb 20; 13(4):e028957.
-
Dabigatran in the treatment and secondary prophylaxis of venous thromboembolism in children with thrombophilia. Blood Adv. 2022 11 22; 6(22):5908-5923.
-
Anticoagulant Effects of Dabigatran on Coagulation Laboratory Parameters in Pediatric Patients: Combined Data from Five Pediatric Clinical Trials. Thromb Haemost. 2022 Sep; 122(9):1573-1583.
-
Use of oral anticoagulants in patients with valvular atrial fibrillation: findings from the NCDR PINNACLE Registry. Am Heart J. 2021 10; 240:58-62.
-
Pharmacokinetic modeling and simulation support for age- and weight-adjusted dosing of dabigatran etexilate in children with venous thromboembolism. J Thromb Haemost. 2021 05; 19(5):1259-1270.
-
Short-Term Cessation of Dabigatran Causes a Paradoxical Prothrombotic State. Ann Neurol. 2021 03; 89(3):444-458.
-
Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial. Lancet Haematol. 2021 Jan; 8(1):e22-e33.
-
Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children. Blood. 2020 02 13; 135(7):491-504.
-
The safety of oral anticoagulants registry (SOAR): A national, ED-based study of the evaluation and management of bleeding and bleeding concerns due to the use of oral anticoagulants. Am J Emerg Med. 2020 06; 38(6):1163-1170.